How many patients are on oral anticoagulant therapy in Denmark? Methods to estimate the number;Hvor mange personer er i peroral antikoagulansbehandling i Danmark? Metoder til estimering af antallet

Ugeskrift for Laeger

Volumn 165, Issue 18, 2003, Pages 1871-1875

  Holm, Tomas ^a   Lassen, Jens Flensted ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; VITAMIN K GROUP;

ADULT; ARTICLE; DENMARK; DRUG UTILIZATION; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; REGISTER; STATISTICAL ANALYSIS; AGED; CLINICAL PRACTICE; DRUG ANTAGONISM; DRUG USE; INTERNATIONAL NORMALIZED RATIO; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PRESCRIPTION; RESIDENTIAL CARE; STATISTICS;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; CATCHMENT AREA (HEALTH); DENMARK; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; REGISTRIES; VITAMIN K;

EID: 0038651193     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Godtfredsen J, Hansen MS, Husted S et al. Antitrombotisk behandlig ved kardiovaskulære sygdomme. Cardiologisk Forum 2002;1(suppl 1):5-33.
2. Nielsen JD, Husted SE, Lassen JF et al. Antikoagulationsbehandling. Ugeskr Læger 2000;162:1247-52.
3. Baglin T. Decentralised anticoagulant care. J Clin Pathol 1998;51:89-90.
4. Lassen JF, Peroral antikoagulansbehandling [ph.d.-afhandl]. Odense: Eget forlag, 1996.
5. Christensen TD, Attermann J, Pilegaard HK et al. Self-management of oral anticoagulant therapy for mechanical heart valve patients. Scand Cardiovasc J 2001;35:107-13,
6. http://www.dkma.dk/statistik.asp/august 2002.
7. Holm T, Lassen JF, Husted S et al. The quality of routine oral anticoagulant therapy in a large geographical area. Dan Med Bull 2002;49:252-5.
8. www.statistikbanken.dk/august 2002.
9. International Committee for Standardization in Haematology, International Committee on Thrombosis and Haemostasis: ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. Thromb Haemost 1985;53:155-6.
10. Husted S, Lassen JF, Nielsen HK et al. Praktiske aspekter ved peroral artikoagulansbehandling. Ugeskr Læger 2001;13(suppl 13):4-31.
11. Jørgersen T, Jespersen J, eds. Antikoagulasjonsbehandling i Norden. Samarbejde mellem NEMT og NORDKEM. SINTEF. Trondheim: Tapir Trykk, 1995.
12. Lassen JF, Jespersen J. INR-målinger i almen praksis og kvaliteten af peroral AK-behandling. Ugeskr Læger 2000;162:3108.
13. Stafford RS, Singer DE. Recent national patterns of warfarin use in atrial fibrillation. Circulation 1998;97:1231-3.
14. http://www.who.int/hpr/ageing/index.htm/august 2002.
15. Steffensen FH, Olesen F, Sørensen HT. Implementation of guidelines on stroke prevention. Fam Pract 1995;12:269-73.
16. Smith P, Arnesen H, Holme I. The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990;323:147-52.
17. Petersen P, Boysen G, Godtfredsen J et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-9.